Rigel Pharmaceuticals, Inc. Q3 2025 Earnings Recap

RIGL Q3 2025 November 6, 2025

Get alerts when RIGL reports next quarter

Rigel Pharmaceuticals reported robust financial performance in Q3 2025, achieving record net product sales of $64.1 million, a 65% year-over-year increase, alongside significant advancements in its development pipeline.

Earnings Per Share Beat

$1.46 vs $0.93 est.

+57.0% surprise

Revenue Beat

69462000 vs 68424040 est.

+1.5% surprise

Market Reaction

1-Day -4.57%

5-Day +0.26%

30-Day +24.86%

See RIGL alongside your other holdings

Add to your portfolio — free

Key Takeaways

Total revenue for Q3 2025 reached $69.5 million, reinforcing strong commercial execution and strategic pipeline expansion.
The company raised its 2025 revenue guidance to a range of $285 million to $290 million, reflecting a growth of 55% to 59% compared to 2024.
Rigel achieved net income of $27.9 million in Q3 and increased cash reserves to $137.1 million, maintaining strong financial discipline.
Key products TAVALISSE, GAVRETO, and REZLIDHIA all demonstrated substantial year-over-year growth, with TAVALISSE alone generating $44.7 million in net sales.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit RIGL on AllInvestView.

Next Q1 2026